PD1 Blockade in Cancer: Impact on Myeloid Cells

摘要

Programmed death 1 (PD1) has emerged as a major inhibitor of antitumor T cells, and anti-PD1 therapies have demonstrated clinical efficacy in multiple cancers. However, the impact of PD1 on other immune cells had remained unclear. A recent study byStrausset al.describes how myeloid cell-intrinsic PD1 signaling limits myelopoiesis in cancer pertinent to anti-PD1 therapies.